Loading company…
Scope Biosciences develops CRISPR-based molecular diagnostic tests.
Founded in 2020 in the Netherlands, Scope Biosciences develops molecular diagnostics using its scope Dx® test, a CRISPR-Cas product designed for on-site use in healthcare and agriculture. The test provides results in under 25 minutes. The company has completed three deals, including a EUR 2.50 mn grant from the European Innovation Council.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in